The FDA approval of SPRAVATO® in 2019 marked the first genuinely new class of antidepressant in over three decades — yet most patients in rural Idaho have never heard of it, let alone had access to it. SPRAVATO® is a nasal spray derived from esketamine and is FDA-approved specifically for treatment-resistant depression (TRD) and major depressive disorder (MDD) with acute suicidal ideation or behavior. At H3O Interventional Psychiatry in Twin Falls, we are the only certified SPRAVATO® provider within 150 miles, which means patients across the Magic Valley finally have local access to this FDA-approved treatment.
Understanding SPRAVATO® vs. IV Ketamine
Understanding the difference between SPRAVATO® and IV ketamine matters, because patients and even some providers sometimes conflate the two. SPRAVATO® (esketamine) is a distinct drug that has received specific FDA approval for TRD and for MDD with acute suicidal ideation or behavior. IV ketamine, by contrast, is used off-label for psychiatric conditions. Both act on the glutamatergic system and both are administered in monitored clinical settings, but they are chemically different, administered differently, and approved for different purposes under different regulatory frameworks. At H3O Interventional Psychiatry, we offer both, and Dr. Nicole Bartlett, DNP, PMHNP-BC, will help you understand which option aligns with your diagnosis and history.
SPRAVATO® is a self-administered nasal spray given under direct clinical supervision at our Twin Falls facility. That supervision requirement is not a formality — it is a regulatory condition of the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) program administered by the FDA. The REMS program exists because SPRAVATO® can cause dissociation, sedation, and blood pressure changes, and patients must be monitored for at least two hours following each dose. Our team stays with you throughout that window, and we ask that every patient arrange transportation rather than driving themselves to or from treatment.
The FDA has approved SPRAVATO® for adults with TRD who have not responded to at least two oral antidepressants, and separately for adults with MDD who are experiencing active suicidal ideation with intent or behavior. These are the only two FDA-approved indications, and we follow those clinical parameters carefully. SPRAVATO® is used in conjunction with an oral antidepressant, not as a standalone therapy, and we will work with you to ensure your full psychiatric regimen is appropriately coordinated. If you are already working with another prescriber, we can collaborate with that provider to integrate SPRAVATO® into your broader care plan.
Removing Barriers to Advanced Care in Southern Idaho
One barrier we hear regularly in our Twin Falls clinic is the sense of disqualification — patients who have been told that advanced treatments are “not available here” and who have accepted that their options are limited to whatever their primary care provider can prescribe. That acceptance is understandable given the geographic reality of southern Idaho, but it is not clinically accurate. H3O Interventional Psychiatry was built to bring interventional psychiatric options to patients who would otherwise have to travel to Boise, Salt Lake City, or beyond. Dr. Bartlett operates with extended hours Monday through Friday so that pursuing SPRAVATO® treatment does not require sacrificing your work schedule.
A second barrier that comes up involves how patients interpret FDA approval. Many people assume that if a medication is available and covered by insurance, it must be the right first step — and conversely, that anything requiring clinical monitoring is inherently dangerous or experimental. SPRAVATO® is an FDA-approved medication that is covered by many insurance plans when prescribed within its approved indications, and its monitoring requirement reflects responsible clinical practice rather than extraordinary risk. We encourage every patient to discuss with their provider what SPRAVATO® involves, what the monitoring period feels like, and what realistic expectations for response look like.
The typical induction phase of SPRAVATO® treatment involves twice-weekly sessions over four weeks, followed by a maintenance schedule that your provider adjusts based on your response. The monitoring period after each dose is spent at our clinic in a comfortable space where you can rest. Most patients describe the experience as a noticeable but manageable shift in perception during the active phase, which resolves within the monitoring window. Results vary by individual, and we will evaluate your response regularly throughout the course of treatment. For a closer look at what a supervised session actually involves, our post on what SPRAVATO® treatment is like in Twin Falls walks through the process in detail.
For patients in Twin Falls, Burley, Rupert, Gooding, and across the Magic Valley who have been living with treatment-resistant depression or severe MDD, SPRAVATO® represents a meaningful clinical advance that is now accessible without driving hours to reach a certified provider. We believe access to FDA-approved treatments should not be a privilege determined by geography, and that commitment is central to why H3O Interventional Psychiatry exists.
Frequently Asked Questions
What is the difference between SPRAVATO® and ketamine?
SPRAVATO® (esketamine) is an FDA-approved nasal spray derived from the S-enantiomer of ketamine. It is a distinct drug from IV ketamine, which is used off-label for psychiatric conditions. SPRAVATO® has specific FDA-approved indications for treatment-resistant depression and MDD with acute suicidal ideation or behavior, while IV ketamine’s psychiatric use is considered off-label.
Who qualifies for SPRAVATO®?
SPRAVATO® is FDA-approved for adults with treatment-resistant depression who have not adequately responded to at least two oral antidepressants, and for adults with major depressive disorder experiencing acute suicidal ideation with intent or behavior. An evaluation with Dr. Nicole Bartlett will determine whether you meet the clinical criteria.
Does insurance cover SPRAVATO®?
Many insurance plans cover SPRAVATO® when it is prescribed within its FDA-approved indications. Coverage varies by plan, and our team can help you navigate the prior authorization process. Discuss with your provider and insurer about what documentation may be required.
Why do I have to stay at the clinic after a SPRAVATO® dose?
SPRAVATO® is subject to a REMS (Risk Evaluation and Mitigation Strategy) program because it can cause dissociation, sedation, and blood pressure changes in some patients. A minimum two-hour monitoring period is required by the FDA after each dose. Our team is with you throughout that window to ensure your safety and comfort.
Can SPRAVATO® be combined with other antidepressants?
Yes — SPRAVATO® is intended to be used alongside an oral antidepressant, not as a standalone treatment. Dr. Bartlett will review your current medications and help you understand how SPRAVATO® fits within your broader psychiatric regimen.
Key Takeaways
- SPRAVATO® (esketamine) is FDA-approved for treatment-resistant depression (TRD) and MDD with acute suicidal ideation or behavior — it is a distinct drug from IV ketamine.
- H3O Interventional Psychiatry in Twin Falls is the only certified SPRAVATO® provider within 150 miles, offering local access for Magic Valley patients.
- Every SPRAVATO® session requires clinical monitoring for at least two hours per FDA REMS requirements — our team is present throughout.
- SPRAVATO® is used alongside an oral antidepressant and is covered by many insurance plans within its approved indications.
- Results vary by individual; an evaluation with Dr. Nicole Bartlett determines whether SPRAVATO® is appropriate for your clinical situation.
Conclusion
SPRAVATO® is one of the most significant advances in depression treatment in a generation, and patients in southern Idaho no longer have to travel out of the region to access it. At H3O Interventional Psychiatry, we have built the infrastructure, earned the certification, and maintained the clinical standards required to offer SPRAVATO® safely and effectively in Twin Falls. If you have been living with treatment-resistant depression and have not found adequate relief through oral antidepressants, we encourage you to reach out, discuss with your provider whether SPRAVATO® fits your clinical picture, and schedule a consultation. You deserve care that keeps up with what medicine has actually achieved.
References
U.S. Food and Drug Administration — SPRAVATO® Approval. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-spravato
SPRAVATO® REMS Program. https://www.spravatorems.com/
National Alliance on Mental Illness (NAMI). https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Esketamine-(Spravato)
American Journal of Psychiatry — Esketamine for Treatment-Resistant Depression. https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2019.19020172
About Dr. Nicole Bartlett
Dr. Nicole Bartlett, DNP, PMHNP-BC, leads H3O Interventional Psychiatry in Twin Falls, Idaho, serving patients across southern Idaho who face geographic barriers to advanced psychiatric care. H3O Wellness is the only TMS provider within 120 miles and the only certified SPRAVATO® provider within 150 miles, offering psychiatric services including TMS, SPRAVATO®, and IV ketamine under one roof for patients with treatment-resistant depression. Dr. Bartlett conducts thorough evaluations weighing each patient’s depression severity, treatment history, medical profile, and practical needs before recommending TMS, SPRAVATO®, ketamine, or combination approaches — with extended hours Monday through Friday to accommodate all schedules.
Medical Disclaimer
The content on this page is intended for educational purposes only and does not constitute medical advice. Information provided by H3O Interventional Psychiatry is not a substitute for professional medical evaluation, diagnosis, or treatment. Results vary by individual, and no outcomes are guaranteed. Always discuss with your provider before making any changes to your mental health treatment plan. If you are experiencing a mental health emergency, please call 988 (Suicide and Crisis Lifeline) or go to your nearest emergency room.